SU2C names researchers to $12 Million “Dream Team” on colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stand Up To Cancer announced the formation of a “Dream Team” of researchers to take on one of the toughest challenges in cancer research and treatment.

The announcement was made at a special event during the 2017 Annual Meeting of the American Association for Cancer Research, SU2C’s Scientific Partner.

“We are urgently in need of new approaches to colorectal cancer,” said Phillip A. Sharp, institute professor at MIT’s Koch Institute for Integrative Cancer Research, Nobel Laureate, and chairman of SU2C’s Scientific Advisory Committee. “We have made great progress in prevention through widespread screening, but new methods are needed to treat colorectal cancer when it actually occurs.”

The SU2C Colorectal Cancer Dream Team, with funding of up to $12 million from SU2C, will be led by Luis Diaz, of Memorial Sloan Kettering Cancer Center as leader, and Charles Fuchs, director of the Yale Cancer Center; Lewis Cantley, director of the Meyer Cancer Center at Weill Cornell Medicine and New York-Presbyterian Hospital; and Zhenghe Wang, of the School of Medicine at Case Western Reserve University, as co-leaders.

More than 50 researchers at six institutions are involved in the team.

“Through a combination of new avenues in immunotherapy, targeted therapeutics, metabolomics, and precision prevention, we believe we can find new ways to fight colorectal cancer and bring new hope to patients,” Diaz said.

The team’s research program will also include clinical trials to investigate drugs that could attack genetic vulnerabilities in many types of colorectal cancer tumors.

“The metabolism of cancer cells, how they process nutrients, is different from normal cells,” Cantley said. “The trials are designed to take advantage of that knowledge and hopefully kill the cells.”

Serving as Dream Team Principals are Ryan Corcoran, Massachusetts General Hospital Cancer Center, and Nilofer Azad, Johns Hopkins University.

Serving as Dream Team Advocates are Anjee Davis, president, Fight Colorectal Cancer; Ivelisse Page, executive director and co-founder, Believe Big Inc.; Joanna Fuchs, patient advocate, Yale University; Martha Raymond, executive director, Michael’s Mission; Thomas Herbert Marsilje; and Vanessa Whiting, president, A.E.S. Management Corp.

The colorectal team is the 20th Dream Team launched by Stand Up To Cancer since its inception in 2008, which has also launched six Translational Research Teams, 46 Innovative Research Grants, and a host of other grants and awards to encourage innovative and collaborative cancer research, with funds committed by philanthropic, organizational, corporate, and individual donors, as well as nonprofit groups working with SU2C.

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login